Texas Attorney General Ken Paxton (R) has joined the Federal Trade Commission and several states in a lawsuit against the World Professional Association for Transgender Health (WPATH), alleging the organization deceptively promoted gender transition procedures and treatments for minors.
What is the lawsuit about?
AG Ken Paxton announced that Texas has joined the Federal Trade Commission in a lawsuit against WPATH, an organization that develops guidelines related to transgender healthcare.
The lawsuit alleges that WPATH promoted medical interventions for minors experiencing gender dysphoria while failing to adequately disclose potential risks and long-term consequences associated with those treatments.
Texas is joined in the lawsuit by the Attorneys General of Alaska, Iowa, and Nebraska.
What are the allegations?
According to the lawsuit, WPATH and its members promoted treatments including:
- Puberty-blocking medications
- Cross-sex hormone therapies
- Surgical procedures related to gender transition
The legal action claims the organization encourages healthcare providers and medical institutions to authorize these treatments while minimizing or failing to disclose potential long-term health consequences.
What is Paxton saying?
AG Ken Paxton: "Any ground that illegally promotes irreversible, life-altering 'transitioning' procedures to kids as safe and necessary will face the full force of the law for harming children."
AG Paxton continued: "We will not allow WPATH or any other organization to illegally promote or perform dangerous 'transitioning' procedures on our kids that leave them with permanent trauma and lifelong health consequences."
Why does this matter?
The lawsuit represents the latest legal challenge involving pediatric gender transition treatments, an issue that has become a major point of debate in state legislatures, medical organizations, and courts across the country.
Texas has previously enacted laws restricting certain gender transition procedures for minors, and this lawsuit expands the state's efforts by targeting organizations involved in developing and promoting treatment standards.
